176 related articles for article (PubMed ID: 35174213)
1. Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer.
Yin B; Ding J; Hu H; Yang M; Huang B; Dong W; Li F; Han L
Front Mol Biosci; 2022; 9():769032. PubMed ID: 35174213
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Xu Y; Li Q; Lin H
Cell Signal; 2024 Mar; 115():111012. PubMed ID: 38113979
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
5. CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.
Jia D; Xiong L; Xue H; Li J
PeerJ; 2023; 11():e14668. PubMed ID: 36643629
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
Front Oncol; 2020; 10():585961. PubMed ID: 33552963
[TBL] [Abstract][Full Text] [Related]
7. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
8. Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer.
Hou X; He S; Zhang D; Yang C; Shi Y; Zhang K
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33090010
[TBL] [Abstract][Full Text] [Related]
9. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
10. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
11. KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma.
Sun Z; Zhou R; Dai J; Chen J; Liu Y; Wang M; Zhou R; Liu F; Zhang Q; Xu Y; Zhang T
Int J Gen Med; 2023; 16():4849-4862. PubMed ID: 37916194
[TBL] [Abstract][Full Text] [Related]
12. CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
Dai F; Duan YL; Feng Q; Song SL; Yang JL; Lv T
J Cancer; 2024; 15(8):2373-2379. PubMed ID: 38495487
[TBL] [Abstract][Full Text] [Related]
13. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
16. Leucyl and Cystinyl Aminopeptidase as a Prognostic-Related Biomarker in OV Correlating with Immune Infiltrates.
Ma Q; Chang L; Wang W; Che L; Song X; Li G; Zhang Y; Chen Y; Gu Z; Ge X
Pharmgenomics Pers Med; 2023; 16():551-568. PubMed ID: 37293607
[TBL] [Abstract][Full Text] [Related]
17. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
19. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
[TBL] [Abstract][Full Text] [Related]
20. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1.
Zheng Y; Wang C; Song A; Jiang F; Zhou J; Li G; Zhang W; Ye J; Ding X; Zhang W; Du Y; Zhang H; Wu H; Song X; Wu Y
Am J Cancer Res; 2020; 10(6):1691-1709. PubMed ID: 32642284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
